3 Monster Stocks in the Making to Buy Right Now
CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.
3 Gene Editing Stocks That Could Grow Your Wealth
Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its long-run potential.
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.
3 Profitable CRISPR Stocks Earning Analysts' Praise
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.
Crispr Therapeutics: Beaten Down But Not Broken
CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program.
Forget Intuitive Surgical: This Stock Is the Next Millionaire Maker
Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.
You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued.
CRISPR Therapeutics is a gene-editing pioneer. Despite its landmark regulatory approvals with Casgevy, its shares have failed to excite the investment community.
